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Background: The current reports on the association of claudin-4 expression with gastric cancer outcome were
inconsistent. Thus, we conducted a meta-analysis to assess the association of claudin-4 expression with the
prognosis and clinical parameters more precisely.
Methods: Systematic searches on PubMed, Embase, and Cochrane Library prior to December 2014 were
performed. The pooled hazard ratio (HR) with its 95 % confidence interval (95 %CI) was used to assess the
prognostic value of claudin-4 expression with gastric cancer patients, and the pooled odds ratio (OR) with its 95
%CI was used to assess the association with clinical parameters.
Results: Nine studies with a total of 1265 gastric cancer patients were included. Overall, the pooled results showed
that over-expression of claudin-4 was associated with a poor survival in gastric cancer patients (HR: 2.01, 95 % CI:
1.62–2.50). Over-expression of claudin-4 was also associated with advanced stage (OR: 1.96, 95 % CI: 1.08–3.56) and
lymphoid node metastasis (OR: 1.72, 95 % CI: 1.05–2.81) of gastric cancer patients. No significant publication bias
was found among the studies (P > 0.05).
Conclusions: This meta-analysis shows that over-expression of claudin-4 is associated with progress of gastric
cancer and poor prognosis of gastric cancer patients.
Keywords: Claudin-4, Gastric cancer, Prognosis, Meta-analysisBackground
Gastric cancer is one of the most common malignant can-
cers of the digestive system. Despite the advancement of
medical treatment, the cancer-related mortality remained
high due to the local tumor invasion and metastasis at the
time of diagnosis [1]. Degradation or breakdown of extra-
cellular matrix and connective tissue surrounding tumor
cells is necessary for the tumor invasion. Tight junctions,
which are one of the structures within the apical junc-
tional complex, act as barriers in epithelial and endothe-
lial cells by mediating adhesion between cells [2]. In the
setting of cancer invasion and metastasis, cancer cells
are often found to exhibit a loss of functional tight
junctions [3].
Claudins are major integral membrane tight junction
proteins, which comprising a 24-member family, and
exhibit tissue-specific expression pattern [4]. Different* Correspondence: nnliwenjing@163.com
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creativecommons.org/publicdomain/zero/1.0/claudin subtypes are coexpressed in specific cell types.
Multiple claudin subtypes often contribute to the forma-
tion of tight junctions. Claudin-4 is the most frequently
deregulated claudins in some cancers [5]. Currently, sev-
eral studies have reported the relationship of claudin-4
expression and gastric cancer risk, but these results are
not inconsistent. For example, Jung et al. [6] analyzed
the data of 72 gastric cancer patients and found that the
over-expression of claudin-4 was significantly correlated
with favorable survival of gastric cancer patients. A
similar result was reported in Ohtani et al. [7] study.
However, in Resnick et al. [8], 124 gastric cancer patients
enrolled and showed that over-expression of claudin-4
was associated with poor survival in gastric cancer pa-
tients. Considering the inconsistent results of current
findings, we, therefore, performed a meta-analysis of all
eligible studies available to explore the relationship of
over-expression of claudin-4 with gastric cancer.distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Search strategy
All methods of this study were performed based on the
meta-analysis of observational studies in epidemiology
(MOOSE). A systematic literature search was performed
using PubMed, Embase, the Cochrane Library, Google
Scholar databases, Chinese National Knowledge Infra-
structure (CNKI), and conference abstracts to identify
relevant articles published prior to December 2014; Search
strategies were carried out using both medical subhead-
ings and free terms. We used a combination of the follow-
ing search string: “Claudin-4”, “Stomach Neoplasms”,
“gastric cancer”, “prognosis”, “prognostic”, “survival”. In
addition, we manually screened the reference lists of in-
cluded studies for further relevant studies. If the identified
studies reported on overlapping populations, we selected
the study that was published more recently or that con-
tained more information.
Selection criteria
Two reviewers (JXL and ZYW) screened the study selec-
tion process independently. Inter-reviewer agreement of
the eligibility of the studies between reviewers was good;
the kappa value was 0.9. Any disagreement was resolved
by arbitration until consensus was achieved. Studies were
eligible for inclusion if (1) gastric cancer patients were di-
agnosed clearly, (2) study is focused on the association of
claudin-4 over-expression with clinical parameters and
prognosis of gastric cancer patients, (3) immunohisto-
chemistry (IHC) was used as the main method to deter-
mine the claudin-4 expression in gastric cancer specimens.
Quality assessment
The quality of each study was assessed using the
Newcastle Ottawa Quality Assessment Scale (NOQAS)
by two independent reviewers [9]. These scales were
used to allocate a maximum of nine points for quality of
selection, comparability, exposure, and outcome of
study participants. The studies considered to be of high
methodological quality (score above 6) were included in
this meta-analysis.
Data extraction
All data were extracted by two independent reviewers
(JXL and ZYW). Discrepancies were resolved by discus-
sions and referring to the contents of the articles. We
extracted the basic study information (name of first
author, year of publication, region or country where the
study was conducted, size of study population), partici-
pant characteristics (gender and age distributions), IHC
methodology (antibody source, dilution, claudin-4 cut-
off value), and clinical parameters (tumor stage, lymph-
oid nodal metastasis, distant metastasis) from each study
and recorded the survival results of each study. Instudies that reported hazard ratios (HRs) in both univar-
iate and multivariate models, we extracted the latter be-
cause these results were more convincing, as there had
been adjustment for potential confounders.
Statistical analysis
We used the odds ratio (OR) to quantitatively determine
the association between claudin-4 expression and clin-
ical parameters of gastric cancer, while the HR was
used for quantitatively evaluating the association of
claudin-4 expression with patients’ survival. For studies
that did not include the point estimates and HR vari-
ance, we used the data available in such studies and ap-
plied the method reported by Tierney et al. [10] to
determine the HR and its 95 % confidence interval (CI).
If a study reported only the survival curve, we extracted
time-to-event data from the Kaplan–Meier curves of
individual studies using Engauge Digitizer 4.1 software
(http://digitizer.sourceforge.net/). Heterogeneity across
studies was checked by a chi-square based on Q test
and the I2 test. I2 values <25 % are an indicator of mild
heterogeneity, I2 values between 25 and 50 % correspond
to moderate heterogeneity, and I2 values >50 % correspond
to large heterogeneity [11]. For a Q statistic P value ≥0.1,
we used a fixed-effects model (Mantel-Haenszel method)
to calculate the pooled estimates; Otherwise, a more
conservative random-effects model (DerSimonian–Laird
method) was used. Sensitivity analysis was performed to
test the reliability of the overall pooled results. Funnel plot
asymmetry was assessed by Egger’s test and Begg’s test. All
statistical tests in this meta-analysis were performed using
Stata 11.2 software (Stata Corp, College Station, TX) with
two-tail P values. A P value less than 0.05 was considered
statistically significant.
Results
Search results and study characteristics
The initial search yielded 79 studies. After screening of
the titles, abstracts, and full-text, a total of nine studies
[6–8, 12–17] were eventually included in this study based
on the predefined criteria. Figure 1 details the selection
process. Among these ten studies, six were from China,
two were from Korea, one was from Japan, and one was
from USA. Altogether, these ten studies recruited a total
of 1265 gastric cancer patients, with sample sizes ranged
from 72 to 189. All the studies used IHC methods for
claudin-4 staining. The claudin-4 positive cut-off value
varied between studies, ranging 25–50 %. Table 1 summa-
rizes the characteristics of the included studies.
Quantitative synthesis
Seven studies with 1030 patients investigated the prog-
nostic value of claudin-4 on the gastric cancer patients,
and the pooled results showed that over-expression of
Fig. 1 Study selection flowchart
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cancer patients (HR: 2.01, 95 % CI: 1.62–2.50, P < 0.001).
No significant heterogeneity across the studies (I2 = 0.0 %,
P = 0.508). See Fig. 2. The Egger’s test (P = 0.762) and
Begg’s test (P = 1.000) suggested no publication bias.
Seven studies with 1026 patients investigated the asso-
ciation between claudin-4 expression and the tumor
stage of gastric cancer. The meta-analysis showed that
over-expression of claudin-4 was associated with ad-
vanced stage of gastric cancer (OR: 1.96, 95 % CI: 1.08–
3.56, P = 0.031), and moderate heterogeneity was foundTable 1 Characteristic of selected studies in the meta-analysis
Author Year/country Patient number Gender (M/F) Age Anti
Li et al. 2014/China 142 94/48 61.4 Invit
Liu et al. 2013/China 72 42/30 48.6 Beck
Zhu et al. 2013/China 329 238/91 57 Zym
Jung et al. 2011/Korea 72 43/29 60.46 DAK
Wu et al. 2011/China 98 59/39 63.5 Abc
Hwang et al. 2010/Taiwan 189 110/79 62 Zym
Ohtani et al. 2009/Japan 124 89/35 66.8 Zym
Kuo et al. 2006/Taiwan 93 56/37 64 San
Resnick et al. 2005/USA 146 76/70 71.1 Zym
NA not availableamong the studies (I2 = 69.0, P = 0.004). See Fig. 3. The
heterogeneity was reduced by removing each study in
turn in the sensitivity analysis, and the sensitivity ana-
lysis result remained similar to the main result. No sig-
nificant publication bias was found among the studies
(Egger’s test: P = 0.125; Begg’s test: P = 0.293).
We found that over-expression of claudin-4 was asso-
ciated with lymphoid node metastasis after we pooled
the data of eight studies with 1119 patients (OR: 1.72,
95 % CI: 1.05–2.81, P = 0.026), but there was moderate
heterogeneity across the studies (I2 = 47.0, P = 0.067).body source Dilution Cut-off (%) Follow-up (month) Quality score
rogen NA 50 NA 7
man NA 25 12–48 8
ed 1:100 50 1–136 9
O 1:200 50 2.7–48.8 8
am NA 50 6–76 8
ed 1:100 50 12–60 8
ed 1:100 50 1–64 8
ta Cruz NA 50 NA 7
ed 1:100 50 12–180 8
Fig. 2 Meta-analysis of claudin-4 expression with survival of gastric cancer patients
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main result after removing each study in turn. Publica-
tion bias was negligible across the studies (Egger’s test:
P = 0.473; Begg’s test: P = 0.911).
However, the pooled results of three studies with 473
patients failed to show the significant association of
claudin-4 with distant metastasis of gastric cancer (OR:
1.10, 95 % CI: 10.70–1.74, P = 0.067), and there was no
significant heterogeneity among the studies (I2 = 0.0, P =
0.851). See Fig. 5. No significant publication bias wasFig. 3 Meta-analysis of claudin-4 expression with clinical stage of gastric cafound among the studies (Egger’s test: P = 0.642; Begg’s
test: P = 1.000).
Discussion
The development and progression of gastric cancer is a
multiple process. It is generally believed that tumorigen-
esis is accompanied by a disruption of tight junctions, a
process that may play a central role in the loss of cohe-
sion and invasiveness in cancers [18]. Studies have
demonstrated that claudins affect cell physiology byncer
Fig. 4 Meta-analysis of claudin-4 expression with lymphoid node metastasis of gastric cancer
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junctions [19, 20]. The alteration of claudin expression is
found to be involved in tumorigenesis in several cancers.
However, the role of claudin-4 in the regulation of
cancer-related cell functions, such as invasion and me-
tastasis, remains controversial [20, 21]. In addition, the
clinical implications of claudin-4 over-expression in vari-
ous cancers and the molecular mechanisms leading to
its dysregulation have remained largely unknown [22].
In the present study, pooled by the data from pub-
lished studies, we found that over-expression of claudin-
4 was associated with poor prognosis of gastric cancer,
advanced clinical stage, and lymphoid node metastasis.Fig. 5 Meta-analysis of claudin-4 expression with distant metastasis of gastThese results are consistent with the previous reports
that claudin-4 participates in the pathogenesis of gastric
cancer by a disruption of the tight junctions, subse-
quently leading to the loss of cohesion and invasiveness
of several cancers [6, 8, 23]. Comparing to the individual
reports, our meta-analysis involves a larger sample size,
thus has greater power to detect the significant associ-
ation. Furthermore, the little publication bias also
guarantees the reliable estimates of our results. When
considering the inconsistent results of current reports,
our results have special clinical significance and high-
light the importance of claudin-4 as a promising thera-
peutic target for gastric cancer.ric cancer
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in pooled analysis of the clinical parameters. In order to
reduce the impact of heterogeneity, we performed sensi-
tivity analysis. We found that heterogeneity was signifi-
cantly reduced while the sensitivity analysis result was in
line with the main results, indicating the reliability of
the pooled results. In this study, the heterogeneity across
studies can likely be attributed to different IHC method-
ologies, including the primary antibody used, antibody
dilutions, and the scoring system applied. With regard
to the association of claudin-4 expression with distant
metastasis of gastric cancer, we failed to show the signifi-
cant association. However, there were only three studies
included; thus, we think this null association may be
caused by small sample size. Therefore, studies with
larger patient cohorts are needed in order to validate
this association.
Although our meta-analysis was robust in identifying a
correlation between claudin-4 over-expression and poor
clinical outcome in gastric cancer, this study should be
interpreted with caution in view of some limitations.
First, heterogeneity was not eliminated entirely although
we conduct a sensitivity analysis, which may have dis-
torted the pooled results. Second, the present meta-
analysis restricted only included studies published in Eng-
lish and Chinese, which may have caused a potential bias.
Third, some HR value could not be obtained from articles
directly; we extracted these data by using recommended
methods [10] from survival curves in the articles, which
unavoidably developed a decrease of reliability. Fourth,
due to limitation of origin data, we could not analyze the
pooled HR either by data type (e.g., data from univariate
or multivariate model) or subgroup analysis (e.g., cut-off
value, membranous or cytoplasmic expression).Conclusions
In conclusion, this meta-analysis shows that over-
expression of claudin-4 is associated with poor prognosis
of gastric cancer patients and leads to progress of gastric
cancer. However, due to limitations of this study, more
studies with standard design (such as IHC method, loca-
tion of claudin-4 expression) are warranted in order to
further verify our results.
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